MedPath

Gastrointestinal and lung cancer, effects of the fish oil intake on nutritional status, quality of life and imunnometabolic outcomes

Not Applicable
Recruiting
Conditions
Gastric neoplasmsColorectal neoplasmsAnus neoplasmsNon-Small-Cell Lung carcinomaIntestinal neoplasms
C04.588.274.476.411.307
C04.588.894.797.520.109.220.249
C16.9
C04.588.274.476.767
C04.588.274.476.411.307.790.040
C04.588.274.476.411
Registration Number
RBR-2xcd99
Lead Sponsor
niversidade Federal de Santa Catarina - UFSC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Individuals with 19 years or older, histopathologic diagnosis of gastric cancer, or colorectal or anal canal or non-small cell lung cancer, ability to start chemotherapy in co-participant institution (CEPON).

Exclusion Criteria

Prior chemotherapy, inability to
oral intake, diagnosis of infectious or inflammatory disease, be allergic to fish and / or derivatives, be pregnant, treatment with statins, ??use of fish oil and/or another supplement containing omega-3 or other polyunsaturated fatty acid in the six months
prior to the study period, continued use of supplements containing antioxidants.

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Decrease in levels of inflammatory markers (TH1 response cytokines - IL-2, IL-4, IL-6, TNF, IFN-y, IL-17A, IL-10) and prostaglandin E2 (PGE2), from quantification of the plasma levels of these biomarkers before (baseline), 5 weeks and after (9 weeks) fish oil supplementation, using ELISA technique of quantification, and comparing with levels of control group;Increased activity of antioxidant enzymes (catalase, glutathione peroxidase and superoxide dismutase) verified through spetophotometric assays in erythrocytes before supplementation and after nine weeks of supplementation with fish oil and comparing with activity of enzymes in control group.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath